One-year outcomes of daratumumab-based vs. non-daratumumab regimens in AL amyloidosis: A propensity-matched real-world study

Chidiebube Ugwu(Jefferson Einstein Philadelphia Hospital), Alankrita Taneja(Sidney Kimmel Cancer Center), Muluken Megiso(Jefferson Hospital), Elvis Obomanu(Jefferson Einstein Philadelphia Hospital), Kelechi Onyenemezu(Nazareth Hospital), Nnamdi J Omenuko(East Tennessee State University), Nneoma Ubah(Montefiore Medical Center), Chidiebere Ezeh(University of Nigeria), Angimar Uriepero(Jefferson Einstein Philadelphia Hospital), Gàbor Varadi(Hadassah Academic College), Tarfa Verinumbe(Albert Einstein College of Medicine)
Blood
November 3, 2025
10.1182/blood-2025-6369
Cited by 0

Related Papers

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
|Blood|1998|1.9k
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
|Blood|1998|1.8k
Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis
|Experimental Hematology|2000|111
Scale-up of antiretroviral treatment access among people living with HIV in Rivers State, Nigeria, 2019--2020
|AIDS|2021|16
Characterizing the Relationship between HIV Peer Support Groups and Internalized Stigma Among People Living with HIV in Nigeria
|AIDS and Behavior|2023|15